

Index

A

- Adenocarcinoma (ADC), 2
 - with acinar configuration, 16
 - histological patterns, 13
 - recurrent molecular alterations, 18
 - small biopsy, 16
 - terminology and criteria, 12
- Adenocarcinoma in situ (AIS), 86
- Adjuvant chemotherapy, 26
- Adjuvant radiotherapy, 26
- Attenuation artifacts, 63

B

- Bevacizumab, 27
- Bronchioloalveolar carcinoma (BAC), 86

C

- Chest radiography, 24
- Computed tomography (CT), 77
- Contrast-enhanced computed tomography (CECT), 24

E

- Elderly Lung Cancer Vinorelbine Italian Study, 27

F

- FDG-PET/CT, 42
- ¹⁸F-FDG PET/CT, 48, 50–53
 - benign etiology, 69
 - evaluation, 48
 - incidental findings, 69
 - infection and inflammation, 63–69
 - maximum intensity projection, 62, 63
 - neoplastic pathology, 71
 - NSCLC, 48

- M staging, 50–53
- N staging, 48
- T staging, 48
- prediction, 53
- prognostication, 55
- radiotherapy planning, 53
- restaging/recurrence, 53
- SCLC, 55
- technical artifacts, 62–63

I

- International Association for the Study of Lung Cancer (IASLC), 3

L

- Large-cell carcinoma, 2
- Lung cancer, 1
 - appropriate site of biopsy, 87
 - asymptomatic distant metastases, 88, 89
 - cavitating lesions, 84
 - in cecum, 91
 - classification, 2
 - clinical features, 3
 - diagnosis, 24
 - with false-positive tuberculous mediastinal adenopathy, 92
 - locoregionally advanced, 94
 - mass-like lesions of, 85
 - metastatic, 95
 - molecular targets, 17–18
 - pathologist role, 9–11
 - pathology, 11
 - postradiation therapy changes in, 93
 - risk factor, 2
 - staging, 24
 - TNM staging, 5, 25, 36
 - in urinary bladder, 90
 - 2015 WHO classification of, 11–14

M

- Magnetic resonance imaging (MRI), 24
- Management, 25, 26
 - early-stage lung cancer
 - nonsurgical, 26
 - surgery, 25
 - locally advanced unresectable lung cancer, 27
 - N2 disease, 26
 - stage IV disease, 27
- Metastatic disease, 41–42

N

- National Institute for Health and Care Excellence (NICE), 2
- Neoadjuvant chemotherapy (NACT), 53
- Nodal disease, 40–41
- Non-small cell lung cancer (NSCLC), 2, 3
 - classification, 10
 - genomic classification, 10
 - immunohistochemical staining, 17
 - management, 28
 - M staging, 50–53
 - N staging, 48
 - targeted therapy, 28
 - T staging, 48

P

- Pancoast's tumours, 40
- Positron emission tomography (PET), 24
 - correction methods, 76
 - isotopes, 78
 - radioisotope decay, 76
 - recent developments, 81
 - reconstruction, 77, 78
 - respiratory gating, 80
 - scanners, 75
 - tracers, 77
 - true event, 76
- Primary tumour
 - downstaging, 42
 - mediastinal invasion on CT, 39
 - metastatic disease, 41–42
 - nodal disease, 40–41
 - recurrent disease, 42
 - superior sulcus tumours, 40

R

- Radiation-induced pneumonitis, 67
- Radiofrequency ablation (RFA), 26
- Radiotherapy, 26
- Real-time Position Management (RPM), 81
- Recurrent disease, 42
- Respiratory artifacts, 62

S

- Sarcoidosis, 64
- Small cell lung cancer (SCLC), 2
 - ¹⁸F-FDG PET/CT, 55
 - management, 28
 - staging of, 5
- Solitary pulmonary nodule (SPN), 48, 86
- Squamous cell carcinoma(s), 2, 12
- Stereotactic body radiotherapy (SBRT), 26
- Superior sulcus tumours, 40

T

- Talc pleurodesis, 66
- Transoesophageal fine-needle aspiration (EUS-FNA), 41
- Tuberculosis
 - cavitating lesions, 84
 - mass-like lesions of, 75
- Tumour downstaging, 42
- Tumour, node and metastasis (TNM) classification, 3

V

- Veterans Administration Lung Cancer Study Group (VALSG) staging system, 5
- Video-assisted thoracoscopic surgery (VATS), 26
- Vocal cords, 69

W

- Warthin's tumor, 69